Dutasteride soft capsules significantly improve the symptoms of benign prostatic hyperplasia by inhibiting 5 α - reductase. The standard dose is 0.5mg per day, and continuous use for 6 months is required to achieve maximum efficacy. The following provides a detailed explanation from four aspects: mechanism of action, clinical efficacy, medication plan, and precautions.

1. Mechanism of action

(1) Double effect inhibition: Simultaneously inhibiting type I and type II 5 α - reductase, reducing dihydrotestosterone levels by more than 90%.

(2) Organizational improvement: Reduce prostate volume by 20-30% and alleviate symptoms of urethral compression.

2. Clinical efficacy

(1) Symptom relief: After 3 months of medication, the International Prostate Symptom Score (IPSS) decreased by an average of 4.5 points.

(2) Urinary flow improvement: the maximum urinary flow rate increased by 1.5-2.0 mL/s, reducing the risk of acute urinary retention by 57%.

3. Medication plan

(1) Standard dose: Take 0.5mg orally at a fixed time daily without adjustment with meals.

(2) Treatment requirements: Evaluate the efficacy of continuous use for at least 6 months, and long-term maintenance treatment can prevent progression.

4. Important precautions

(1) Delayed onset: Symptom improvement takes 2-4 weeks, and complete effect may take 6-12 months.

(2) Dose warning: Overdose use is prohibited. Exceeding 0.5mg per day will not enhance efficacy but increase side effects.

(3) Special monitoring: PSA and liver function indicators should be regularly checked before and during medication.